Rafael Holdings, Inc. key statistics and ratios
In fiscal 2026, Rafael Holdings, Inc. had return on equity of -36.9% and a net margin of -3390.7%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2016Jul 2016 | 2017Jul 2017 | 2018Jul 2018 | 2019Jul 2019 | 2020Jul 2020 | 2021Jul 2021 | 2022Jul 2022 | 2023Jul 2023 | 2024Jul 2024 | 2025Jul 2025 | 2026Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | 12.7% | 2.5% | −266.5% | −95.2% | −219.0% | <−999% | <−999% | −672.4% | <−999% | <−999% | <−999% |
| Return on equity | 1.5% | 0.3% | −14.6% | −4.3% | −9.4% | −19.3% | −111.9% | −1.9% | −37.7% | −34.6% | −36.9% |
| Return on assets | — | 0.2% | −11.5% | −3.6% | −7.7% | −15.9% | −91.5% | −1.7% | −35.2% | −28.9% | −30.1% |
| Effective tax rate | 38.7% | 32.4% | — | — | — | — | — | — | — | — | — |
| R&D as % of revenue | — | — | 22.8% | 20.8% | 48.7% | 611.8% | >999% | >999% | 654.6% | >999% | >999% |
| SG&A as % of revenue | 49.3% | 66.4% | 126.3% | 178.9% | 185.7% | >999% | >999% | — | — | — | — |
Financial health
- Short-term assets cover short-term liabilities $26m of assets due within a year against $11m of liabilities due within a year.
- Short-term assets cover long-term liabilities $26m short-term assets against $98,000 of longer-dated liabilities.
- More cash than debt $22m of cash against $2,000 of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$30m of operating cash flow against $2,000 of debt.
- Operating profit covers interest at least five times over Operating income of −$33m against $333,000 of interest.
Moat
Weak moat
How hard Rafael Holdings's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -15.0% of total assets over 9 years.
- Durability 10 / 20
Operating margin has been a median -3516.1%; its worst year was -16111.0%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 7 years, at a median -80.7% of revenue.
- Discipline 0 / 20
The diluted share count rose 226.0% over five years; stock-based pay has been a median 231.5% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).
Compare with peers
- Medicinova Inc statistics
- Shattuck Labs, Inc. statistics
- Longeveron Inc. statistics
- Dare Bioscience, Inc. statistics
- Cartesian Therapeutics, Inc. statistics
Head to head: MNOV vs RFLRFL vs STTKLGVN vs RFL
More: Biotechnology stocks compared, Health Care sector, rankings of US companies